Aeterna Zentaris gets to SPA agreement with FDA for AEZS-108 Phase 3 trial in endometrial cancer Aeterna Zentaris Inc.S. Food and Medication Administration on a particular Protocol Assessment for the next Phase 3 sign up trial in endometrial tumor with its doxorubicin peptide conjugate, AEZS-108. The SPA agreement claims that the proposed trial protocol design, clinical endpoints and planned analyses are acceptable to the FDA to support a regulatory submission. ‘AEZS-108's innovative targeted approach could offer a new treatment option for females with endometrial cancer and provide the Business with a significant market opportunity.’.Because dental care routinely involves treating pain and emergencies, dentists might encounter substance-seeking individuals who complain of pain more severe than anticipated predicated on the nature of their teeth condition, who report lost prescriptions for opioid discomfort medications, or who just seek dental treatment sporadically, lead author Carrigan Parish, a co-employee research scientist from Columbia University Mailman School of Public Health in NEW YORK, said in a university information release. The survey found that older dentists were less likely to screen for medication use. Dentists young than 53 were much more likely than older dentists to believe that it was their role to conduct medication screening, 62 % vs. 47 %, the scholarly study noted.